(Q34206001)

31 July 2017

title

Chemotherapy: A new standard combination for recurrent ovarian cancer? (English)

1 reference

31 July 2017

1 reference

1 reference

Robert C Bast

1

0 references

author name string

Maurie Markman

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Nature Reviews Clinical Oncology

31 July 2017

published in

1 reference

31 July 2017

volume

7

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

559-560

1 reference

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956193

Hypersensitivity reactions to antineoplastic agents: an overview

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956193

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956193

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956193

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956193

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956193

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2956193

Adriamycin induced immunomodulation: dependence upon time of administration

28 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.152

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

31 March 2020

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.152

A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20877420

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2010.152

1 reference

Dimensions Publication ID

31 July 2017

1050605067

0 references

Fatcat ID

release_v56kmvwszfam3ldh4qpu5px4py

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v56kmvwszfam3ldh4qpu5px4py

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

2956193

1 reference

31 July 2017

1 reference